Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 5, 2006, Pages 506-514

  Koppe, Manuel J ^a   Oyen, Wim J G ^a   Bleichrodt, Robert P ^a   Verhofstad, Albert A ^a   Goldenberg, David M ^b   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Colon carcinoma; Gemcitabine; Peritoneal metastases; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; GEMCITABINE; MONOCLONAL ANTIBODY MN 14 I 131; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PERITONEUM METASTASIS; PETECHIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; SKIN TOXICITY; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PERITONEAL NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY;

EID: 33751000765     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.506     Document Type: Article

References (22)

1. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814S.
2. Schlom J, Eggensperger D, Colcher D, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992;52:1067.
3. Behr TM, Blumenthal RD, Memtsoudis S, et al. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 2000;6:4900.
4. Boerman OC, van Schaijk FG, Oyen WJ, et al. Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 2003;44:400.
5. Cardillo TM, Blumenthal R, Ying Z, et al. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer 2002;97:386.
6. Gold DV, Schutsky K, Modrak D, et al. Low-dose radioimmunotherapy ([90]Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929S.
7. 90Yttrium- DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer 2004;109:618.
8. Pauwels B, Korst AE, Pattyn GG, et al. Cell-cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003;57:1075.
9. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995;6(Suppl 6):7.
10. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1996;88:1193.
11. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Rex 2003;9:3712.
12. Koppe MJ, Soede AC, Pels W, et al. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. Int J Cancer 2003;106:965.
13. Koppe MJ, Bleichrodt RP, Soede AC, et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45:1224.
14. Wang H, Li M, Rinehart JJ, et al. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: In vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 2004;10:1633.
15. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a, and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978;15: 429.
16. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth 1984;72: 77.
17. Koppe MJ, Oyen WJ, Bleichrodt RP, et al. Combination therapy using the cyclooxygenase-2 inhibitor parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Immunol Immunother 2006;55:47.
18. Pauwels B, Korst AE, Lardon F, et al. Combined modality therapy of gemcitabine and radiation. Oncologist 2005;10:34.
19. Mani S, Kugler JW, Knost JA, et al. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer. Invest New Drugs 1998;16:275.
20. Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218.
21. Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 1996;23:65.
22. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24:S7.